FDA “Unmet Medical Need” Definition Can Be Moving Target – ImClone CEO

Biotech product development would be helped by more flexibility from FDA in applying the standard of an "unmet medical need," ImClone CEO Harlan Waksal suggested during a June 3 Manhattan Institute Capitol Hill briefing on the future of medical progress